0001193125-17-249862.txt : 20170807 0001193125-17-249862.hdr.sgml : 20170807 20170807160558 ACCESSION NUMBER: 0001193125-17-249862 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170807 ITEM INFORMATION: Other Events FILED AS OF DATE: 20170807 DATE AS OF CHANGE: 20170807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MANNKIND CORP CENTRAL INDEX KEY: 0000899460 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133607736 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-50865 FILM NUMBER: 171011524 BUSINESS ADDRESS: STREET 1: 25134 RYE CANYON LOOP STREET 2: SUITE 300 CITY: VALENCIA STATE: CA ZIP: 91355 BUSINESS PHONE: 6617755300 MAIL ADDRESS: STREET 1: 25134 RYE CANYON LOOP STREET 2: SUITE 300 CITY: VALENCIA STATE: CA ZIP: 91355 8-K 1 d435827d8k.htm 8-K 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 7, 2017

 

 

MannKind Corporation

(Exact name of Registrant as specified in its charter)

 

 

 

Delaware   000-50865   13-3607736

(State or other jurisdiction of

incorporation or organization)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

25134 Rye Canyon Loop, Suite 300

Valencia, California

   91355
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (661) 775-5300

N/A

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. of Form 8-K):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 8.01 Other Events.

On August 4, 2017, the board of directors of MannKind Corporation ( “MannKind”) resolved to voluntary delist its common stock from The Tel Aviv Stock Exchange Ltd., or TASE. Under applicable Israeli law, the delisting of MannKind’s common stock from trading on the TASE is expected to become effective three months from the date of request. During this time, MannKind’s common stock will continue to be traded on the TASE.

MannKind’s common stock continues to be listed for trading on The NASDAQ Global Market, or NASDAQ, and all shares of common stock traded on the TASE are expected to transfer to NASDAQ once the delisting of MannKind’s common stock from the TASE becomes effective.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

            MANNKIND CORPORATION
Dated:   August 7, 2017     By:   /s/ David Thomson
      Name:   David Thomson, Ph.D., J.D.
      Title:   Corporate Vice President, General Counsel and Secretary